{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:16:54Z","timestamp":1787170614302,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1756-8722-5-75","type":"journal-article","created":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T23:14:13Z","timestamp":1355440453000},"source":"Crossref","is-referenced-by-count":62,"title":["Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies"],"prefix":"10.1186","volume":"5","author":[{"given":"Ali","family":"McBride","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Westervelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,13]]},"reference":[{"key":"271_CR1","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1056\/NEJMra0904569","volume":"364","author":"SC Howard","year":"2011","unstructured":"Howard SC, Jones DP, Pui CH: The tumor lysis syndrome. N Engl J Med. 2011, 364: 1844-1854. 10.1056\/NEJMra0904569.","journal-title":"N Engl J Med"},{"key":"271_CR2","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","volume":"28","author":"J Cortes","year":"2010","unstructured":"Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J: Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone\u2013results of a multicenter phase III study. J Clin Oncol. 2010, 28: 4207-4213. 10.1200\/JCO.2009.26.8896.","journal-title":"J Clin Oncol"},{"key":"271_CR3","first-page":"31","volume":"5","author":"GA Wetzstein","year":"2002","unstructured":"Wetzstein GA: Tumor lysis syndrome-a treatment guide. Oncology. 2002, 5: 31-4.","journal-title":"Oncology"},{"key":"271_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2169\/internalmedicine.49.3153","volume":"49","author":"S Joshita","year":"2010","unstructured":"Joshita S, Yoshizawa K, Sano K, Kobayashi S, Sekiguchi T, Morita S: A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. Intern Med. 2010, 49: 991-994. 10.2169\/internalmedicine.49.3153.","journal-title":"Intern Med"},{"key":"271_CR5","first-page":"1","volume":"2","author":"KQ Qian","year":"2009","unstructured":"Qian KQ, Ye H, Xiao YW, Bao YY, Qi CJ: Tumor lysis syndrome associated with chemotherapy in primary retroperitoneal soft tissue sarcoma by ex vivo ATP-based tumor chemo-sensitivity assay (ATP-TCA). Int J Gen Med. 2009, 2: 1-4.","journal-title":"Int J Gen Med"},{"key":"271_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/qjmed\/hcn129","volume":"102","author":"C Shenoy","year":"2009","unstructured":"Shenoy C: Acute spontaneous tumor lysis syndrome in a patient with squamous cell carcinoma of the lung. QJM. 2009, 102: 71-73. 10.1093\/qjmed\/hcn129.","journal-title":"QJM"},{"key":"271_CR7","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1200\/JCO.2008.19.4308","volume":"26","author":"GY Noh","year":"2008","unstructured":"Noh GY, Choe DH, Kim CH, Lee JC: Fatal tumor lysis syndrome during radiotherapy for non-small-cell lung cancer. J Clin Oncol. 2008, 26: 6005-6006. 10.1200\/JCO.2008.19.4308.","journal-title":"J Clin Oncol"},{"key":"271_CR8","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1200\/JCO.2005.02.8753","volume":"24","author":"D Ajzensztejn","year":"2006","unstructured":"Ajzensztejn D, Hegde VS, Lee SM: Tumor lysis syndrome after treatment with docetaxel for non-small-cell lung cancer. J Clin Oncol. 2006, 24: 2389-2391. 10.1200\/JCO.2005.02.8753.","journal-title":"J Clin Oncol"},{"key":"271_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1385\/MO:22:2:203","volume":"22","author":"M Kurt","year":"2005","unstructured":"Kurt M, Onal IK, Elkiran T, Altun B, Altundag K, Gullu I: Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma. Med Oncol. 2005, 22: 203-6. 10.1385\/MO:22:2:203.","journal-title":"Med Oncol"},{"key":"271_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3324\/haematol.12327","volume":"93","author":"J Hochberg","year":"2008","unstructured":"Hochberg J, Cairo MS: Tumor lysis syndrome: current perspective. Haematologica. 2008, 93: 9-13. 10.3324\/haematol.12327.","journal-title":"Haematologica"},{"key":"271_CR11","first-page":"26","volume":"49","author":"SM Ahamed","year":"2006","unstructured":"Ahamed SM, Varma RS, Mathew T, Hamide A, Badhe BA: Spontaneous tumour lysis syndrome associated with non-Hodgkin's lymphoma\u2013a case report. Indian J Pathol Microbiol. 2006, 49: 26-28.","journal-title":"Indian J Pathol Microbiol"},{"key":"271_CR12","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1080\/10428190600765798","volume":"47","author":"SC Howard","year":"2006","unstructured":"Howard SC, Pui CH: Pitfalls in predicting tumor lysis syndrome. Leuk Lymphoma. 2006, 47: 782-785. 10.1080\/10428190600765798.","journal-title":"Leuk Lymphoma"},{"key":"271_CR13","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","volume":"26","author":"B Coiffier","year":"2008","unstructured":"Coiffier B, Altman A, Pui CH, Younes A, Cairo MS: Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008, 26: 2767-2778. 10.1200\/JCO.2007.15.0177.","journal-title":"J Clin Oncol"},{"key":"271_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","volume":"127","author":"MS Cairo","year":"2004","unstructured":"Cairo MS, Bishop M: Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004, 127: 3-11. 10.1111\/j.1365-2141.2004.05094.x.","journal-title":"Br J Haematol"},{"key":"271_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0002-9343(93)90174-N","volume":"94","author":"KR Hande","year":"1993","unstructured":"Hande KR, Garrow GC: Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med. 1993, 94: 133-139. 10.1016\/0002-9343(93)90174-N.","journal-title":"Am J Med"},{"key":"271_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3816\/SCT.2005.n.012","volume":"2","author":"FE Mott","year":"2005","unstructured":"Mott FE, Esana A, Chakmakjian C, Herrington JD: Tumor lysis syndrome in solid tumors. Support Cancer Ther. 2005, 2: 188-191. 10.3816\/SCT.2005.n.012.","journal-title":"Support Cancer Ther"},{"key":"271_CR17","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1200\/JCO.2007.14.7603","volume":"26","author":"G Krishnan","year":"2008","unstructured":"Krishnan G, D\u2019Silva K, Al-Janadi A: Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma. J Clin Oncol. 2008, 26: 2406-2408. 10.1200\/JCO.2007.14.7603.","journal-title":"J Clin Oncol"},{"key":"271_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ijgo.2010.02.005","volume":"109","author":"H Godoy","year":"2010","unstructured":"Godoy H, Kesterson JP, Lele S: Tumor lysis syndrome associated with carboplatin and paclitaxel in a woman with recurrent endometrial cancer. Int J Gynaecol Obstet. 2010, 109: 254-10.1016\/j.ijgo.2010.02.005.","journal-title":"Int J Gynaecol Obstet"},{"key":"271_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/00000441-200203000-00007","volume":"323","author":"GS Habib","year":"2002","unstructured":"Habib GS, Saliba WR: Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: a case report and review of the literature. Am J Med Sci. 2002, 323: 155-157. 10.1097\/00000441-200203000-00007.","journal-title":"Am J Med Sci"},{"key":"271_CR20","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1055::AID-CNCR7>3.0.CO;2-3","volume":"85","author":"MP Castro","year":"1999","unstructured":"Castro MP, VanAuken J, Spencer-Cisek P, Legha S, Sponzo RW: Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. Cancer. 1999, 85: 1055-1059. 10.1002\/(SICI)1097-0142(19990301)85:5<1055::AID-CNCR7>3.0.CO;2-3.","journal-title":"Cancer"},{"key":"271_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/ndt\/16.1.188","volume":"16","author":"J Stoves","year":"2001","unstructured":"Stoves J, Richardson D, Patel H: Tumour lysis syndrome in a patient with metastatic melanoma treated with biochemotherapy. Nephrol Dial Transplant. 2001, 16: 188-189. 10.1093\/ndt\/16.1.188.","journal-title":"Nephrol Dial Transplant"},{"key":"271_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.4103\/0970-9185.86611","volume":"27","author":"A Verma","year":"2011","unstructured":"Verma A, Mathur R, Chauhan M, Ranjan P: Tumor lysis syndrome developing intraoperatively. J Anaesthesiol Clin Pharmacol. 2011, 27: 561-563. 10.4103\/0970-9185.86611.","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"271_CR23","doi-asserted-by":"crossref","first-page":"610969","DOI":"10.1155\/2010\/610969","volume":"2010","author":"M Opyrchal","year":"2010","unstructured":"Opyrchal M, Figanbaum T, Ghosh A, Rajkumar V, Caples S: Spontaneous tumor lysis syndrome in the setting of B-cell lymphoma. Case Report Med. 2010, 2010: 610969-1\u20133","journal-title":"Case Report Med"},{"key":"271_CR24","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.4161\/cbt.5.12.3610","volume":"5","author":"B Riccio","year":"2006","unstructured":"Riccio B, Mato A, Olson EM, Berns JS, Luger S: Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature. Cancer Biol Ther. 2006, 5: 1614-1617. 10.4161\/cbt.5.12.3610.","journal-title":"Cancer Biol Ther"},{"key":"271_CR25","first-page":"387","volume":"22","author":"J Barquero Romero","year":"2005","unstructured":"Barquero Romero J, Catalina Fern\u00e1ndez I, Hern\u00e1ndez S\u00e1ez C, Jim\u00e9nez Morales JL, Garc\u00eda de la Llana F: Spontaneous tumor lysis syndrome in a patient with non-Hodgkin's lymphoma. An Med Interna. 2005, 22: 387-389.","journal-title":"An Med Interna"},{"key":"271_CR26","first-page":"828","volume":"53","author":"SK Sharma","year":"2005","unstructured":"Sharma SK, Malhotra P, Kumar M, Sharma A, Varma N, Singh S: Spontaneous tumor lysis syndrome in acute lymphoblastic leukemia. J Assoc Physicians India. 2005, 53: 828-830.","journal-title":"J Assoc Physicians India"},{"key":"271_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ajh.2830470212","volume":"47","author":"AM Jasek","year":"1994","unstructured":"Jasek AM, Day HJ: Acute spontaneous tumor lysis syndrome. Am J Hematol. 1994, 47: 129-131. 10.1002\/ajh.2830470212.","journal-title":"Am J Hematol"},{"key":"271_CR28","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/SMJ.0b013e318137a665","volume":"100","author":"CJ Lin","year":"2007","unstructured":"Lin CJ, Hsieh RK, Lim KH, Chen HH, Cheng YC, Wu CJ: Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer. South Med J. 2007, 100: 916-917. 10.1097\/SMJ.0b013e318137a665.","journal-title":"South Med J"},{"key":"271_CR29","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s005200100276","volume":"9","author":"G Pentheroudakis","year":"2001","unstructured":"Pentheroudakis G, O\u2019Neill VJ, Vasey P, Kaye SB: Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases. Support Care Cancer. 2001, 9: 554-557. 10.1007\/s005200100276.","journal-title":"Support Care Cancer"},{"key":"271_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3346\/jkms.2001.16.1.115","volume":"16","author":"IS Woo","year":"2001","unstructured":"Woo IS, Kim JS, Park MJ, Lee MS, Cheon RW, Chang HM: Spontaneous acute tumor lysis syndrome with advanced gastric cancer. J Korean Med Sci. 2001, 16: 115-118.","journal-title":"J Korean Med Sci"},{"key":"271_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00000421-199502000-00015","volume":"18","author":"NT Sklarin","year":"1995","unstructured":"Sklarin NT, Markham M: Spontaneous recurrent tumor lysis syndrome in breast cancer. Am J Clin Oncol. 1995, 18: 71-73. 10.1097\/00000421-199502000-00015.","journal-title":"Am J Clin Oncol"},{"key":"271_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/archinte.1977.03630130065016","volume":"137","author":"DR Crittenden","year":"1977","unstructured":"Crittenden DR, Ackerman GL: Hyperuricemic acute renal failure in disseminated carcinoma. Arch Intern Med. 1977, 137: 97-99. 10.1001\/archinte.1977.03630130065016.","journal-title":"Arch Intern Med"},{"key":"271_CR33","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1001\/archinte.1974.00320150023002","volume":"133","author":"CM Kjellstrand","year":"1974","unstructured":"Kjellstrand CM, Cambell DC, von Hartitzsch B, Buselmeier TJ: Hyperuricemic acute renal failure. Arch Intern Med. 1974, 133: 349-359. 10.1001\/archinte.1974.00320150023002.","journal-title":"Arch Intern Med"},{"key":"271_CR34","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","volume":"149","author":"MS Cairo","year":"2010","unstructured":"Cairo MS, Coiffier B, Reiter A, Younes A, TLS Expert Panel: Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010, 149: 578-586. 10.1111\/j.1365-2141.2010.08143.x.","journal-title":"Br J Haematol"},{"key":"271_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JBM.S9648","volume":"2","author":"LD Kennedy","year":"2011","unstructured":"Kennedy LD, Koontz S, Rao K: Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies. J Blood Med. 2011, 2: 1-6.","journal-title":"J Blood Med"},{"key":"271_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3816\/SCT.2005.n.008","volume":"2","author":"AS Michallet","year":"2005","unstructured":"Michallet AS, Tartas S, Coiffier B: Optimizing management of tumor lysis syndrome in adults with hematologic malignancies. Support Cancer Ther. 2005, 2: 159-166. 10.3816\/SCT.2005.n.008.","journal-title":"Support Cancer Ther"},{"issue":"Suppl 2","key":"271_CR37","doi-asserted-by":"publisher","first-page":"ii2","DOI":"10.1093\/rheumatology\/kep086","volume":"48","author":"M Doherty","year":"2009","unstructured":"Doherty M: New insights into the epidemiology of gout. Rheumatology (Oxford). 2009, 48 (Suppl 2): ii2-ii8. 10.1093\/rheumatology\/kep086.","journal-title":"Rheumatology (Oxford)"},{"key":"271_CR38","unstructured":"National Library of Medicine: MedlinePlus: Uric acid \u2013 blood: http:\/\/www.nlm.nih.gov\/medlineplus\/ency\/article\/003476.htm ,"},{"key":"271_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/annonc\/mdh029","volume":"15","author":"H van den Berg","year":"2004","unstructured":"van den Berg H, Reintsema AM: Renal tubular damage in rasburicase: risks of alkalinisation. Ann Oncol. 2004, 15: 175-176. 10.1093\/annonc\/mdh023.","journal-title":"Ann Oncol"},{"key":"271_CR40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/0026-0495(72)90124-2","volume":"21","author":"A Ablin","year":"1972","unstructured":"Ablin A, Stephens BG, Hirata T, Wilson K, Williams HE: Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinol. Metabolism. 1972, 21: 771-778. 10.1016\/0026-0495(72)90124-2.","journal-title":"Metabolism"},{"key":"271_CR41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","volume":"19","author":"CH Pui","year":"2001","unstructured":"Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B: Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001, 19: 697-704.","journal-title":"J Clin Oncol"},{"key":"271_CR42","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","volume":"97","author":"SC Goldman","year":"2001","unstructured":"Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001, 97: 2998-3003. 10.1182\/blood.V97.10.2998.","journal-title":"Blood"},{"key":"271_CR43","unstructured":"Elitek [package insert]: 2011, sanofi-aventis U.S, LLC, Bridgewater, NJ"},{"key":"271_CR44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1078155210364180","volume":"17","author":"RW Knoebel","year":"2011","unstructured":"Knoebel RW, Lo M, Crank CW: Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. J Oncol Pharm Pract. 2011, 17: 147-154. 10.1177\/1078155210364180.","journal-title":"J Oncol Pharm Pract"},{"key":"271_CR45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0609.2010.01457.x","volume":"85","author":"M Giraldez","year":"2010","unstructured":"Giraldez M, Puto K: A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults. Eur J Haematol. 2010, 85: 177-179.","journal-title":"Eur J Haematol"},{"key":"271_CR46","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1345\/aph.1P296","volume":"44","author":"AN Vines","year":"2010","unstructured":"Vines AN, Shanholtz CB, Thompson JL: Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. Ann Pharmacother. 2010, 44: 1529-1537. 10.1345\/aph.1P296.","journal-title":"Ann Pharmacother"},{"key":"271_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2710.2008.00994.x","volume":"34","author":"M Campara","year":"2009","unstructured":"Campara M, Shord SS, Haaf CM: Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach. J Clin Pharm Ther. 2009, 34: 207-213. 10.1111\/j.1365-2710.2008.00994.x.","journal-title":"J Clin Pharm Ther"},{"key":"271_CR48","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1592\/phco.28.6.685","volume":"28","author":"DJ Reeves","year":"2008","unstructured":"Reeves DJ, Bestul DJ: Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy. 2008, 28: 685-690. 10.1592\/phco.28.6.685.","journal-title":"Pharmacotherapy"},{"key":"271_CR49","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1592\/phco.26.2.242","volume":"26","author":"DA Hutcherson","year":"2006","unstructured":"Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M: Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy. 2006, 26: 242-247. 10.1592\/phco.26.2.242.","journal-title":"Pharmacotherapy"},{"key":"271_CR50","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1592\/phco.26.6.806","volume":"26","author":"AM McDonnell","year":"2006","unstructured":"McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD: Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy. 2006, 26: 806-812. 10.1592\/phco.26.6.806.","journal-title":"Pharmacotherapy"},{"key":"271_CR51","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/sj.bmt.1705379","volume":"37","author":"S Trifilio","year":"2006","unstructured":"Trifilio S, Gordon L, Singhal S, Tallman M, Evens A, Rashid K: Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant. 2006, 37: 997-1001. 10.1038\/sj.bmt.1705379.","journal-title":"Bone Marrow Transplant"},{"key":"271_CR52","doi-asserted-by":"crossref","unstructured":"McBride A, Lathan SC, Boehmer L, Augustin KA, Butler SM, Westervelt PW: A comparative evaluation of single fixed-dosing and weight-based dosing of rasburicase for tumor lysis syndrome. \u2009-Pharmacotherapy, in press","DOI":"10.1002\/phar.1198"},{"key":"271_CR53","volume-title":"Ann Oncol","author":"S Vadhan-Raj","year":"2011","unstructured":"Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB: A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2011, \u2009-Epub ahead of print"},{"key":"271_CR54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.leu.2403566","volume":"19","author":"S Jeha","year":"2005","unstructured":"Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S: Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005, 19: 34-38.","journal-title":"Leukemia"},{"key":"271_CR55","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1345\/aph.1D111","volume":"37","author":"AC Lee","year":"2003","unstructured":"Lee AC, Li CH, So KT, Chan R: Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother. 2003, 37: 1614-1617. 10.1345\/aph.1D111.","journal-title":"Ann Pharmacother"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-5-75.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-8722-5-75\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-5-75.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T09:24:58Z","timestamp":1714728298000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-5-75"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["271"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-5-75","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]},"article-number":"75"}}